<DOC>
	<DOCNO>NCT00765687</DOCNO>
	<brief_summary>A multicenter Prospective Study ass screen method , parameter NTX efficacy safety zoledronic acid treatment addition anti-tumor therapy patient non-small cell cancer bone metastasis china .</brief_summary>
	<brief_title>Screening Non Small Cell Lung Cancer With Bone Metastasis Efficacy Safety Research Receiving Bisphosphonates</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1 . Age &gt; 18 , either sex 2 . Histologically confirm nonsmall cell cancer 3 . One bone metastasis least confirm image ( X ray , CT others ) 4 . Without receive zoledronic acid 5 . Life expectancy &gt; 6 M 6 . ECOG &lt; = 2 7 . Signed ICF 1 . Women pregnant lactation 2 . Patients hyperostosis 3. brain metastasis ( exception without symptom Metastasis Lesions control 4 . Previous current treatment bisphosphonates , bone protecting , cytotoxic target therapy 5 . Severe comorbidity type may interfere assessment patient study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>